• SenesTech, a rodent fertility control product provider, is projecting an increase in demand for its Evolve(TM) Soft Bait
• This follows the rising cases of human leptospirosis in New York, an infection associated with exposure to rat urine
• Evolve offers a humane approach to controlling the rodent population, with the potential for complete elimination in 12 to 18 months
• Evolve contributes a significant chunk of SenesTech’s revenue, and the company projects that this will continue to be the case given recent developments

SenesTech (NASDAQ: SNES), a rodent fertility control product provider, and inventor of the only EPA-registered contraceptive for male and female rats, is expecting an increase in the demand for its product offering in the wake of the rising cases of human leptospirosis, particularly in New York. As an infection associated with exposure to rat urine, the rising cases have highlighted New York’s worsening rat problem and further prompted the need for more sustainable and practical solutions (https://ibn.fm/HSkgl).

Human leptospirosis has been linked to residential or occupational exposure to rat urine in environments such as soil and water, as well as materials contaminated with rat urine, such as trash bags or bins containing food waste. Symptoms of the condition include coughing, diarrhea, vomiting, jaundice, rash, and conjunctival suffusion. If left untreated, it can lead to kidney failure, liver damage, respiratory distress, and even meningitis.

Previously, the city employed various methods of controlling rat populations, including rodenticides, and even a “rat czar” was tasked with dealing with the issue. Given the inefficiency of these approaches, earlier in the year, a new bill was proposed by an Upper West Side City Council Member, seeking to ban the use of rodenticide in the city’s war on rats. The move sought to explore more humane methods with guaranteed results in the long term.

“This is not a problem we can kill our way out of. It’s time to embrace these more common sense and humane methods,” noted Jakob Shaw, a special project manager for People for the Ethical Treatment of Animals (https://ibn.fm/PmYT4).

In its earlier venture into exploring rodent contraceptives, New York City had used SenesTech’s ContraPest(R) as an alternative to rodenticide. Given its liquid form, it proved challenging to use despite posting a rat reduction of up to 68% in controlled studies. In subsequent long term field studies, ContraPest showed reductions in rats up to 90%. SenesTech, however, now has its new soft bait product, Evolve(TM), launched in January 2024, and proving extremely popular due to its ease of use and effectiveness. Studies have shown that the product could help reduce rat populations by 50% in just six months.

“If you’ve gotten the whole population on birth control, you should see close to a complete elimination of that population in 12 to 18 months,” noted Dan Palasky, SenesTech’s Chief Technical Officer (“CTO”). “You’re not controlling the death rate. You’re controlling the birth rate,” he added (https://ibn.fm/1OjPY).

With the cases of leptospirosis hitting 24 in 2023, higher than in any prior year, it is essential now, more than ever, to address the rat menace in the city. Given this mounting pressure, SenesTech anticipates a growth in demand for its Evolve soft bait. Since its launch, SenesTech has seen an uptick in demand, and Evolve is already contributing a significant portion of the company’s revenue. The company expects this trajectory to continue, even as it works to introduce a soft bait contraceptive product for mice.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• Cannabis retail dispensaries in Arizona have grown to upwards of 168 locations as of January 2024
• Nonetheless, only 1% of Arizona’s commercial properties are eligible for use by the cannabis industry
• Zoned Properties has been a key partner for the industry in helping cannabis companies establish a physical retail presence
• The company has recently announced the approval of a $1 million share buyback plan

The legalized sale of recreational cannabis in Arizona has grown from strength to strength. Possession and cultivation of cannabis across the state became legal on November 30, 2020, with the state-licensed sale of recreational cannabis commencing on January 22, 2021 making Arizona the quickest state in U.S. history to begin retail sales post recreational legalization. Cannabis sales in the state drove over $1.4 billion in revenues in 2023, with the number of dispensaries swelling to 292 as of January 2024 (https://ibn.fm/ky6yg). Nevertheless, further expansion for the industry is easier said than done; at present, only 1 percent of Arizona’s commercial real estate properties are applicable to cannabis operators, imposing a further constraint on the growth and development of the state’s cannabis retail market.

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States, has been amongst the early leaders in facilitating the transition of the cannabis industry towards the physical retail space. The company maintains a portfolio of six investment properties located across Arizona, Michigan and Illinois; with each of its leased properties occupied by commercial cannabis-linked businesses, the company currently enjoys a 100% occupancy rate with a weighted average lease term of over 10 years.

Zoned Properties has been amongst the leaders in identifying and procuring registered cannabis facilities, which can subsequently be sub-leased to the cannabis industry. Bryan McLaren, Chairman and CEO of Zoned Properties elaborated on the company’s methodology during a recent interview with the Bell2Bell podcast (https://ibn.fm/CtsVE).

“Our company and our team go into these state marketplaces and we identify, qualify and get these properties approved that can be utilized as regulated cannabis facilities. In the best-case scenario, what we’re doing is securing a piece of retail real estate – an old bank, an old restaurant, an old quick service retail location – getting that property approved to be used as a cannabis site called a retail dispensary and leasing that property out to a third-party tenant with a cannabis license in that location under a long-term lease agreement.”

Zoned Properties’ unique business model has translated into a faster rate of operational growth, with the company recently revealing that it had acquired a further two sites for use as potential dispensary locations. Separately, the company has looked to combine its ambitious focus on growth with a desire to maximise total shareholder returns; Zoned Properties recently announced that its Board of Directors has approved a stock repurchase program, pursuant to which the company was authorized to purchase up to $1 million of its common stock over an unlimited time period (https://ibn.fm/IehV5).

“As our business continues to outperform in a challenging overall operating environment, we are thrilled to announce this share repurchase program. The approval of this program demonstrates the management teams and board’s confidence in our prospects for the future, ongoing operational strength, and sound capital structure,” stated McLaren. “As we scale the investment portfolio, we are keeping conservative in our capital allocation strategy while also acknowledging the significant valuation gap between our public valuation and tangible book value. Due to this, it is crucial for us to be adaptable and make sure we are doing everything possible to increase shareholder value. As always, we remain committed in our strategic focus, and look forward to updating shareholders on our progress,” he continued.

For more information, visit the company’s website at www.ZonedProperties.com.

NOTE TO INVESTORS: The latest news and updates relating to ZDPY are available in the company’s newsroom at https://ibn.fm/ZDPY

• SOBRsafe, providing the latest in transdermal alcohol detection solutions, has signed another new customer, one that provides full continuum care, from inpatient detox and residential treatment to outpatient services, and has now installed SOBRcheck(TM) in each of its four facilities to enable point-of-care screening
• The customer is also evaluating SOBRsafe’s wearable band, SOBRsure(TM), for continuous monitoring in an outpatient application
• The new Florida client is one of sixteen new accounts that SOBRsafe secured during the first quarter of 2024
• The global alcohol sensor market was valued at $2.3 billion in 2022 and is expected to grow at a CAGR of 13.7%, resulting in a value of $6.3 billion by 2030

SOBRsafe (NASDAQ: SOBR), a provider of next-generation transdermal alcohol detection solutions, recently announced that they have signed a hardware/software agreement with a four-facility behavioral health provider based in Florida. (https://ibn.fm/7cxba).

The customer provides the full continuum of care, from inpatient detox and residential treatment to outpatient services, and has now installed SOBRcheck(TM) in each of its four facilities to enable point-of-care screening. The customer is also evaluating SOBRsafe’s wearable band, SOBRsure(TM), for continuous monitoring in an outpatient application.

The new client is one of sixteen new accounts that SOBRsafe secured during the first quarter of 2024. These new accounts represent a jump in growth for the company, driven by products that offer non-invasive, efficient, hygienic and connected alcohol detection solutions that legacy alcohol detection technologies can’t match.

The global alcohol sensor market was valued at $2.3 billion in 2022 and is expected to grow at a CAGR of 13.7%, resulting in a value of $6.3 billion by 2030 (https://ibn.fm/jRJbc). Factors fueling market growth include rising alcohol consumption rates, stricter laws pertaining to alcohol consumption, and more effective technologies that facilitate detection and enforcement.

SOBRsafe currently offers the following products to help with alcohol detection in the behavioral health and justice sectors:

• SOBRsafe(TM): Committed to its mission of preserving lives, enhancing productivity, generating significant economic advantages, and fostering positive behavioral change, SOBRsafe has developed the patent-pending SOBRsafe platform. This platform enables non-invasive alcohol detection, real-time reporting, and historical data aggregation on a scalable level. SOBRsafe offers a versatile solution applicable across various sectors including behavioral health, fleet and facility safety, youth drivers, and judicial markets.
• SOBRcheck(TM): SOBRcheck represents the company’s stationary identification and alcohol monitoring solution, delivering swift, targeted alcohol tests at specific points in time. In a hygienic and real-time manner, SOBRcheck authenticates user identity while determining alcohol presence or absence. SOBRcheck delivers immediate results securely to administrators, aiding in the effective management of existing substance abuse policies.
• SOBRsure(TM): SOBRsure introduces the company’s transdermal wearable for alcohol detection. Providing continuous mobile alcohol monitoring, SOBRsure discreetly identifies alcohol presence in the body in real-time. SOBRsure also offers app-based alcohol detection alerts, precise location tracking, and notifications for band removal.

SOBRsafe Director of Commercial Development Eddie Kilroy, said the new Florida customer historically used breathalyzers for select check-ins, but felt these legacy devices were too inefficient and invasive for uniform entry screening. “With SOBRcheck, the provider can verify the absence of alcohol in just 10 seconds or less, in a humane and cost-effective manner. The customer is streamlining operations with automatic results reporting, and electronic records searchable by individual and location,” Kilroy explained. “Switching to SOBRcheck has empowered them to enhance and expand their screening protocols, while likely reducing attempts to subvert the testing process.”

For more information, visit the company’s website at www.SOBRsafe.com. 

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

• SUIC CEO Hank Wang recently joined Bell2Bell Podcast host Stuart Smith to discuss the company’s operations and business model, recent milestones, and plans for 2024
• The venture financing and support company, through its I.Hart Group and Boom Fintech subsidiaries, has entered into agreements that set the stage for significant expansion
• SUIC’s I.Hart Group recently signed a brand corporation agreement with 7-Eleven, expected to promote the company’s long-term growth
• The company’s Boom Fintech is working on financing that will support the creation of a revolutionary B2B financing platform and boost supply chain integration for suppliers
• SUIC expects to significantly expand its product markets, making 2024 its best year yet, according to Hank

SUIC Worldwide Holdings (OTC: SUIC), a provider of research and development, venture financing, and investment for public and private companies, was featured in a recent episode of The Bell2Bell Podcast. SUIC CEO Hank Wang joined host Stuart Smith to discuss the company’s operations and business model, recent milestones, and plans for 2024 (https://ibn.fm/dy633).

According to Mr. Hank, SUIC targets opportunities to enhance and streamline existing supply chain and financial processes. The company is the largest shareholder and major operating partner of Beneway Holdings Group, Ltd. USA (“Beneway USA”), which itself is the parent company of I.Hart Group Taiwan, a company that operates 150 global franchised locations under a variety of brands and products, and Boom Fintech, a fintech company that develops and offers an all-in-one platform designed for merchants.

Over the last few months, both I.Hart Group and Boom Fintech have made substantial strides that bring SUIC closer to its expansion goals. In February, I.Hart, whose portfolio of brands and products includes MONGA(C) Taiwan style fried chicken, flower tea drinks, cloud kitchen management, AI smart machines, dumplings, and more, signed a brand cooperation agreement with 7-Eleven Group, Taiwan’s largest convenience store chain with more than 6,800 stores countrywide. The agreement opens up MONGA(C) Fried Chicken’s multi-channel distribution in Taiwan and through 7-Eleven’s international network of stores (https://ibn.fm/1MLUH).

This agreement, SUIC believed, also opens doors for more cooperation with U.S. brands and promotes overall business expansion, a belief that Hank reaffirmed during the recent interview. Hank noted that the cooperation with 7-Eleven represents “an unprecedented prospect to promote our long-term growth,” further noting that the company will leverage its fast-growing competitive affiliations to “offer additional value to customers in different parts of the world.” In addition, and separately, I.Hart is working on integrating more successful brands into its family, targeting 25 different brands to enter the US franchise market in 50 states. And as Hank put it in the interview, the company hopes to replicate I.Hart Group’s unique multi-brand model in the U.S.

On its part, Boom Fintech, which holds nine revolutionary fintech patents, recently reported to work with BD Bankers to access credit of up to $100 million in intellectual property (“IP”) financing intended to support the creation of a revolutionary B2B financing platform for merchants and franchisees and boost supply chain integration for suppliers (https://ibn.fm/JfHzb).

The efforts of both I.Hart Group and Boom Fintech are expected to accelerate Beneway’s plans for an initial public offering (“IPO”). Beneway intends to file the S-1 form with the Securities and Exchange Commission (“SEC”) later this year as part of its plans to list on a national stock exchange in what is expected to maximize SUIC’s corporate and shareholder value, according to Hank. In addition to the planned IPO, SUIC has additional plans for 2024.

“SUIC expects to significantly expand our product markets, making 2024 its best year yet,” explained Hank. “Looking forward, SUIC will continue to introduce more co-branding products in the U.S. with other prestigious brands to expand our business. [In addition,] we would like to focus on Fintech through industry supply chain integration, global chain and franchise expansion, and other supply chain integrations to enhance and streamline existing processes and establish new and exciting business models that will create revolutionary products and services.”

To listen to the interview, please visit https://ibn.fm/vViFQ

For more information, visit the company’s website at www.SinoUnitedCo.com.

NOTE TO INVESTORS: The latest news and updates relating to SUIC are available in the company’s newsroom at https://ibn.fm/SUIC

Executives and professionals of the biopharma and medical device realm are invited to attend the 8th Decentralized & Hybrid Clinical Trial conference organized by DGE, May 15-16, 2024, in Philadelphia, PA. The event focuses on optimizing the technical processes, regulatory compliance, and design adaptability of remote clinical trials.

The conference is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries.

During COVID-19, remote and decentralized clinical trials (DCTs) came into practice. Since then, the application of decentralized methods for clinical trials has grown phenomenally. Thus, clinical trial teams have to be prepared and equipped to incorporate the relevant technologies for decentralized methods. This conference explores insights into challenges and offers solutions for selecting the right technologies for patients and sites, understanding FDA guidelines, overcoming logistical hurdles, and much more.

Experts conducting speaker sessions will also talk about how the power of AI can be harnessed for various clinical trial processes such as attaining patient data in DCTs, and also when solving issues of tech affordability, bias, and inconsistent data management. Additional topics include the importance of home sampling for decentralized trials, and uses of eConsent.

The event is meticulously curated to address challenges and offer solutions to the clinical trial industry. DGE offers a phenomenal networking platform to meet, learn, and connect with the right professionals and influencers. Connect with industry leaders, showcase unique ideas and presentations, and get the latest updates to stay ahead of the competition.

To know more, please visit https://ibn.fm/r97GX.

• More than half of Americans have attended a music festival, indicating lucrative potential for music and art destinations
• GTVH recently closed on the acquisition of ABI Create, a premier event-management and production company
• With the invaluable resources ABI Create brings to the table, the future of Destino Ranch looks more promising than ever

With Coachella still fresh in music lovers’ memories, it’s only natural to look at what other amazing music festivals might be looming in the future. Destino Ranch comes to mind. A new project focused on becoming an international destination where nature and technology combine to create unforgettable experiences such as outstanding music festivals, Destino Ranch is being developed by Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment.

Officially called the Coachella Valley Music and Arts Festival, Coachella is held over two weekends at the Empire Polo Club in Indio, California, in the Coachella Valley in the Colorado Desert. The event traditionally features an array of musical artists from different music genres, including rock, pop, indie, hip hop and more; the festival also includes art installations and sculptures.

This year, Coachella saw record attendance, with organizers reporting an estimated 300,000 people flocking to Indio (https://ibn.fm/Vr1u8). In addition, Coachella’s revenue is impressive, bringing in $115 million collectively from ticket, food and beverage sales and generating around $700 million for the local economy in Indio and surrounding cities each year (https://ibn.fm/Z8IJc).

There’s definitely an eager audience for events such as music and art festivals. In fact, a Marketing Chart study reported that “overall, roughly one-third (34%) of American adults surveyed report having been to more than one music festival, while an additional fifth (20%) say they’ve been once. As such, some 54% of U.S. adults have been to at least one music festival” (https://ibn.fm/mxLB2).

Clearly, Golden Triangle Ventures and Lavish Entertainment are on to something. Most recently the company took a significant step forward in the development of Destino Ranch with the acquisition of ABI Create, a premier event-management and production company (https://ibn.fm/XPvbI). Founded by Marco Antonio Moreno, who was recently named president and COO of Lavish Entertainment, ABI Create has delivered high-quality productions for a range of large-scale installations at major music festivals, sporting events and conventions across the United States, including the NFL Super Bowl, San Diego and New York Comic Con events, EDC and Camp EDC, Bonnaroo Music Festival, the Waste Management Phoenix Open, Arnold Palmer Invitational, Burning Man and more.

The completed acquisition will transition ABI Create into a wholly owned subsidiary of Lavish Entertainment, strengthening Lavish’s position in the entertainment industry through ABI’s well-known reputation and proven track record of executing high-level projects. Headquartered in Las Vegas, ABI’s comprehensive suite of services includes event organization, management, production, logistics, site planning, permitting, construction, contracting, custom design and fabrication.

With the invaluable resources ABI Create brings to the table, the future of Destino Ranch looks more promising than ever. With access to nearly 22,000 visitors traveling through the area every day, the ranch could quickly become a modern art and music festival mecca. In fact, current plans call for the destination location to include an immersive, world-class art installation gallery with rotating exhibits as well as a large-scale music venue with state-of-the-art staging and production, all carefully designed to complement the beautiful natural attributes of the surrounding Mojave Desert.

“This acquisition of ABI Create sets the stage for us to begin showcasing all other synergistic divisions within Lavish that will support all resources, relationships and partnerships within the ABI portfolio of offerings,” said Steffan Dalsgaard, CEO of Golden Triangle Ventures. “Our goal is to develop ABI into a one-stop-shop, event-management business within Lavish that will hold a complete suite of event management and development services. This aims to complement all internal projects and productions and will potentially support outside business opportunities that can provide fundamental synergies to our ultimate plan of building a complete entertainment enterprise.”

Golden Triangle Ventures is a multifaceted consulting company that operates as a parent business pursuing ventures in the health, entertainment and technology sectors, as represented by the three-point golden triangle, along with other sectors that provide synergistic value to these three core divisions. The company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services.

For more information, visit the company’s website at www.GoldenTriangleInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

• SenesTech’s Evolve(TM) Soft Bait has been proposed to be used in New York City to control its growing rat population
• In a bill tabled by Upper West Side Council Member Shaun Abreu, the city will explore contraception for rats and will start with a 10-block area
• SenesTech’s CTO notes that the city should see close to complete elimination of the population in 12-18 months, not by just controlling the death rate, but by controlling the birth rate as well
• For SenesTech, this move helps affirm the superiority of its products. In addition, it serves as a sign of even bigger things to come

On Thursday, April 11, Flaco, an escaped zoo owl, was found dead with raised levels of rodenticide in his system in New York City, having consumed poisoned rats for sustenance. This was a wake-up call, highlighting the ineffectiveness of the current approach to controlling the city’s rat population and its cost to pets, wildlife, and birds of prey (https://ibn.fm/aF3pC). As a result, the event prompted involved parties to explore alternative, more effective, and more humane approaches to controlling this rat problem, with contraceptives proving to be the viable option.

SenesTech (NASDAQ: SNES), a rodent fertility control product and service provider, and the inventor of the only EPA-registered contraceptive for male and female rats, has been rapidly growing with its unique rodent control solutions, defined by its two main offerings – ContraPest(R) liquid, and Evolve(TM) Soft Bait, both of which have demonstrated impressive results in controlling pest populations through fertility control. The city of New York is exploring the use of Evolve, owing to its shelf life, safety profile and overall effectiveness.

Studies have shown that two rats alone can multiply to 15,000 in just one year. While poisoning and controlling their death rate has proven ineffective and dangerous for other animals, contraception is showing to be an excellent option to explore, particularly since, for a controlled population, one can achieve complete elimination in 12-18 months.

“If you’ve gotten the whole population on birth control, you should see close to a complete elimination of that population in 12 to 18 months. You’re not controlling the death rate. You’re controlling the birth rate,” noted Dan Palasky, SenesTech’s Chief Technical Officer (https://ibn.fm/PReR4).

With the introduction of a new bill by an Upper West Side Council Member, the city is set to, hopefully once and for all, deal with the rat menace that has posed a challenge for every generation of New Yorkers. Various approaches have been explored, from the hiring of a “rat czar” in 2023 to the push to put trash out in boxes as opposed to bags to reduce the amount of food served up to rats (https://ibn.fm/PjiwW). While it holds true that rodents can never be eradicated, contraception is a viable option in managing their population, all within a reasonable timeline. This is achieved without the risk of poisoning other animals, as was the case with Flaco.

“Rat birth control is a promising non-toxic solution to remediating heavily infested areas without dumping lethal poisons all over our city’s streetscape,” noted Shaun Abreu, an Upper West Side City Council Member.

“We can’t poison our way out of the rat problem, but we can certainly do a lot of damage trying,” he added.

Abreu’s pilot program is proposed to start with a 10-block area, with a six-month study to gain a baseline understanding of rodent populations. This will then be followed by six months of birth control. SenesTech is optimistic that its Evolve Soft Bait will yield impressive results over that period, highlighting the product’s overall efficacy while stamping the company’s position as a leader in its space. Already, the company has seen major interest in its Evolve product, and this move by the city of New York is seen as affirming the product’s superiority while serving as a sign of even bigger things to come.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem
• Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024
• GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path
• The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings it closer to offering a tolerable oral delivery option for diabetes treatment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recognizes the tremendous potential in the treatment of type 2 diabetes and obesity, and looks to address it through its patented DehydraTECH(TM) drug delivery technology that offers improved delivery of bioactive compounds. The confidence in its technology, as evidenced by the success of previous clinical studies, has allowed it to double down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. The company is optimistic that the studies will yield positive results, not just in the potential treatment of diabetes but also in weight management, which has been directly linked to diabetes.

According to the Centers for Disease Control and Prevention (“CDC”), more than one in three Americans today are at increased risk for type 2 diabetes. This represents about 98 million Americans, with 81% not knowing they are at such a risk (https://ibn.fm/VG8YI). Studies showed a massive spike in overall incidences of type 2 diabetes between 2002 and 2018, with one of the main cited risk factors being obesity. The CDC noted that of those diagnosed with the condition, 89.8% of them were overweight or obese, as defined by a body mass index (“BMI”) of 25 kg/m2 or higher. This was further compounded by physical inactivity, with 31.9% of those diagnosed reporting getting less than 10 minutes a week of moderate or vigorous activity (https://ibn.fm/3Ass4).

In March, Lexaria announced details of its upcoming 12-week animal study WEIGHT-A24-1 that will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination (https://ibn.fm/TIcIT). Results will guide additional human investigations.

The company recently received independent third-party ethics review board approval for its GLP-1 human pilot study #2, seeking to explore the oral delivery of GLP-1 drugs. For Lexaria, this marks a significant milestone that brings it closer to offering a more effective and tolerable oral delivery option for diabetes treatment and weight loss management (https://ibn.fm/CyRPR).

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO.

“I am excited about this study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” he added.

Previous Lexaria studies have demonstrated that DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms. Already, GLP-1R agonists have been shown to penetrate the brain and activate a subset of GLP-1R-expressing neurons in the arcuate nucleus to produce weight loss. With the upcoming studies, Lexaria looks to evidence that DehydraTECH processing of GLP-1 drugs can enable even faster penetration into brain tissue, ultimately improving overall efficiency in weight loss and blood sugar control. Its management is optimistic that it will replicate the success of previous studies and looks forward to kickstarting the undertaking.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The growing call for court-administered electronic monitoring services remains, as evidenced by a recent deadly Pacific Northwest domestic violence case in which a judge had previously denied a victim’s petition for requiring the suspect to wear an ankle monitor
• Israel-based SuperCom Ltd. has dedicated its suite of PureSecurity products to help governments economically track and monitor individuals at risk for initiating new dangerous situations
• The company has focused its recent efforts on the North American market, while also making inroads in Europe where it recently received over $5 million in sales orders that it will fulfill over the next few months
• SuperCom’s recently announced financial reports highlight the company’s growing success at building its gross margin, revenues, and profits, including a reported 2,350 percent increase in EBITDA

A series of new orders for electronic monitoring technology to bolster European governments’ security infrastructure is strengthening the position of SuperCom (NASDAQ: SPCB) in the EM market.

The recent sales orders for SuperCom’s PureSecurity Suite of products amount to more than $5 million in revenues, orders that the growing electronic-monitoring (“EM”) security solutions provider expects to fulfill within the next three months.

“We are pleased to continue our collaboration with European government customers, further solidifying our dedication to enhancing public safety through our innovative products and solutions,” SuperCom President and CEO Ordan Trabelsi stated in a news release about the requisitions (https://ibn.fm/hqgCG). “This demonstrates the continued validation of our cutting-edge technology, our steadfast dedication to project delivery, and the invaluable relationships we’ve cultivated with our discerning customers.”

SuperCom is celebrating its growth after recently releasing its financial reports for the Q4 period and the year-end results for 2023. The financial reports showed the company’s gross margin grew to 41.4 percent, its EBITDA grew by 2,350 percent and gross profits rose 60 percent (https://ibn.fm/eycFr).

The company offers an end-to-end electronic monitoring solution with state-of-the-art GPS tracking in real time, secured communication and other monitoring technologies.

The PureProtect and PureOne products, which were rolled out during the year, provide improved protection to families suffering from domestic violence and an all-in-one GPS tracking ankle bracelet monitoring solution. The products have the potential to save lives in a society where domestic conflicts too often turn violent.

A Washington state domestic violence case that gained the attention of Pacific Northwest residents in late April (https://ibn.fm/vBH3L) served as a very recent example of the concerns these cases bring and the need for technological solutions to provide people with protection. Following the kidnapping of a young child and the death of two women, media reports noted one of the victims had sought a court order requiring the suspect to wear an electronic ankle monitor under the provisions of the Tiffany Hill Act, but the court denied the request (https://ibn.fm/erpBj).

SuperCom’s solutions also supports alcohol and drug substance treatment program monitoring, house arrest monitoring, and inmate monitoring. The monitors are easily concealable to reduce concerns about stigmatizing their wearers and include an ultra-lightweight base station with long battery life.

“Since 2018, SuperCom has secured over 50 new multi-year government projects. Our strong growing reputation as a premium provider of electronic monitoring solutions and services enhanced our market position with each new customer win,” Ordan said in a discussion of the year-end financial report (https://ibn.fm/fTjDu).

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

Attended by thousands of people worldwide, Finovate conferences are recognized as exclusive events, providing unmatched networking and growth opportunities within the fintech industry. Fintech leaders, entrepreneurs, innovators, senior bankers, investors and financial institutions are all invited to attend the Finovate Spring event being held on May 21-22, 2024, in Marriott Marquis San Francisco, San Francisco, CA. FinovateSpring 2024 is the much-awaited showcase of technology innovations in the financial and banking sectors.

Experience the future of finance with FinovateSpring 2024, a transformational event featuring a dynamic lineup of industry leaders who will share valuable insights into the future of finance and technology. Organizational speakers for the event include J.P. Morgan, Cornerstone Advisers, Charles Schwab, U.S. Bank, BNY Mellon, HSBC, University of California, Women in Payments, Wells Fargo, Cota Capital & more.

Innovation in the Finance Landscape

FinovateSpring serves as a catalyst of innovation, redefining finance with creativity, collaboration, and customer-centricity. This celebrated event provides startups and established businesses with a platform to showcase the latest innovations and unique solutions shaping the finance industry. The event will feature innovative product demos, showcasing the latest concepts and technologies in the finance industry. From AI-driven payment solutions to blockchain-powered banking, the unique solutions provide a glimpse into a fast developing and smarter financial era.

FinovateSpring is a unique opportunity for individuals looking to connect with like-minded visionaries to unlock new possibilities. As a hub for inspiration and creativity, the event is a perfect place to meet industry leaders and attend dynamic interactive panel discussions. Experts will share their perspectives on the evolving finance trends that will shape the future of finance. They will also provide unique solutions to tackle persistent challenges and drive innovation forward.

Registration for FinovateSpring 2024 is now open.

To learn more, please visit https://ibn.fm/cMczz